Akorn has had a busy two years in court following a flurry of data integrity woes that led former merger partner Fresenius to walk away from their deal. Now, it’s putting one issue to rest by settling with investors who lost money during the tumultuous stretch.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,